Search

Abstract Background Gout is caused by monosodium urate (MSU) crystals deposition to trigger immune response. A recent study suggested that inhibition of Class I Histone deacetylases (HDACs) can significantly reduce MSU crystals-induced inflammation. However, which one of HDACs members in response to MSU crystals was still unknown. Here, we investigated the roles of HDAC3 in MSU crystals-induced gouty inflammation. Methods Macrophage specific HDAC3 knockout (KO) mice were used to investigate inflammatory profiles of gout in mouse models in vivo, including ankle arthritis, foot pad arthritis and subcutaneous air pouch model. In the in vitro experiments, bone marrow-derived macrophages (BMDMs) from mice were treated with MSU crystals to assess cytokines, potential target gene and protein. Results Deficiency of HDAC3 in macrophage not only reduced MSU-induced foot pad and ankle joint swelling but also decreased neutrophils trafficking and IL-1β release in air pouch models. In addition, the levels of inflammatory genes related to TLR2/4/NF-κB/IL-6/STAT3 signaling pathway were significantly decreased in BMDMs from HDAC3 KO mice after MSU treatment. Moreover, RGFP966, selective inhibitor of HDAC3, inhibited IL-6 and TNF-α production in BMDMs treated with MSU crystals. Besides, HDAC3 deficiency shifted gene expression from pro-inflammatory macrophage (M1) to anti-inflammatory macrophage (M2) in BMDMs after MSU challenge. Conclusions Deficiency of HDAC3 in macrophage alleviates MSU crystals-induced gouty inflammation through inhibition of TLR2/4 driven IL-6/STAT3 signaling pathway, suggesting that HDAC3 could contribute to a potential therapeutic target of gout.

During the Al-killed steel continuous casting process, the molten steel corrosion and the accumulation of alumina inclusion deposits affect the submerged entry nozzle (SEN) wall surface, including the surface morphologies of the smooth wall, porous refractory wall, and clogged wall. The SEN wall surface morphology affects the boundary layer structure and alumina inclusions transport. In this study, a physical modeling method was adopted, and the surface morphologies simulation was realized by filling up the natural porous refractory material and inserting the real clog material in the polymethyl methacrylate SEN model. The velocity in the boundary layer was measured using the particle image velocimetry (PIV) technology, and the alumina inclusions transport path in the boundary layer was calculated by MATLAB software. The MATLAB codes combined the velocity data from the PIV measurement results and the inclusion transport equation. The four-quadrant analysis showed that sweep and ejection events existed in the boundary layer. The fluctuations of the velocity and the turbulent kinetic energy in the normal direction were increased in the porous refractory and the clogged wall boundary layer when the sweep and ejection events existed. The transport of the alumina inclusions with a diameter of 1–15 μm was affected by the ejection and the sweep events. The alumina inclusions moved toward the boundary in the sweep event. During the sweep event, the transport path of alumina inclusions with 1 μm diameter was close to the boundary; the alumina inclusions were more easily attached to the boundary. The alumina inclusions escaped from the boundary in the ejection event. In the porous refractory and the clogged walls, the alumina inclusion transport path in the normal direction was increased. When the SEN wall’s morphologies changed from smooth wall to porous refractory wall and clogged wall, the sweep event area proportion increased from 10.17% to 39.77%, and the ejection event area proportion decreased from 32.96% to 9.24%. Moreover, the sweep event’s probability increased from 25.83% to 28.24% when the morphologies of the SEN wall changed from smooth wall to porous refractory wall and clogged wall, which will increase the alumina inclusion deposition rate in the porous refractory wall and the clogged wall boundary.

BackgroundHematopoietic stem cell transplantation (HSCT) for haematological disorders. Graft-versus-host disease (GVHD), a cause of morbidity and mortality is treated with corticosteroids. However, patients with steroid-refractory GVHD after HSCT have a poor prognosis. Ruxolitinib, a selective Janus kinase inhibitor, is a novel treatment strategy for steroid-refractory GVHD.ObjectivesTo assess the efficacy of ruxolitinib for the treatment of steroid-refractory GVHD and analyse its adverse effects.Study designMeta-analysis.Search methodsRandomised controlled trials (RCTs) and non-RCTs of ruxolitinib-based therapy in patients with steroid-refractory GVHD were found in the Cochrane Central Register of Controlled Trials, EMBASE, PubMed, and Web of Science in March 2021. Outcomes included overall response rate, survival, and adverse effects. The Methodological Index for Non-randomised Studies (MINORS) and the Cochrane collaboration risk-of-bias tool were used to assess methodological quality. Funnel plots, Egger's test, and the trim and fill method were used to assess publication bias.ResultsIn total, 1470 studies were identified; 19 studies (17 non-RCTs, 2 RCTs) involving 1358 patients met our inclusion criteria. Survival rates at the longest follow-up in non-RCTs, were 57.5% (95% CI 46.9-67.4) and 80.3% (95% CI 69.7-87.9) for acute GVHD (aGVHD) and chronic GVHD (cGVHD), respectively. In non-RCTs, the overall response was 74.9% (95% CI 66.6-81.8, I2 = 49%) in aGVHD and 73.1% (95% CI 62.5-81.6, I2 = 49%) in cGVHD. In aGVHD, the response rates were gastrointestinal, 61.4-90.2%; skin, 52.5-80.6%; and liver, 41.8-71.8%. In cGVHD, the response rates were gastrointestinal, 30.1-70.4%; skin, 30.1-84.4%; lung, 27.0-83.0%; and mouth 3.5-98.1%. In addition, a lower aGVHD grade and moderate cGVHD were associated with a better clinical response. Common adverse events were cytopenia and infectious complications.ConclusionsOur systematic review and meta-analysis indicated that ruxolitinib therapy could be a potentially effective and safe treatment for patients with steroid-refractory GVHD.

BACKGROUND: The toll-like receptor (TLR)4-interleukin1β (IL1β) signaling pathway is involved in the monosodium urate (MSU)-mediated inflammation. The aim of this present study was to determine whether the TLR4 gene rs2149356 SNP is associated with gouty arthritis (GA) susceptibility and whether rs2149356 SNP impacts the TLR4-IL1β signaling pathway molecules expression. METHODS AND FINDINGS: The rs2149356 SNP was detected in 459 GA patients and 669 control subjects (containing 459 healthy and 210 hyperuricemic subjects). Peripheral blood mononuclear cells (PBMCs) TLR4 mRNA and serum IL1β were measured in different genotype carriers, and correlations between TLR4 gene SNP and TLR4 mRNA, IL1β were investigated. The frequencies of the genotype and allele were significantly different between the GA and control groups (P